Herndon Christopher M, Dankenbring Dawn M
J Pain Palliat Care Pharmacother. 2014 Jun;28(2):109-16. doi: 10.3109/15360288.2014.908993. Epub 2014 May 12.
The use of acetaminophen is currently under increased scrutiny by the US Food and Drug Administration (FDA) due to the risk of intentional and more concerning, unintentional overdose-related hepatotoxicity. Acetaminophen is responsible for an estimated 48% of all acute liver failure diagnoses. The purpose of this study is to evaluate patient perception and knowledge of the safe use and potential toxicity of acetaminophen-containing products. The authors conducted a descriptive, 2-week study using a convenience sample from a large family medicine clinic waiting room. Survey questions assessed ability to identify acetaminophen, knowledge of the current recommended maximum daily dose, respondent acetaminophen use patterns, common adverse effects associated with acetaminophen, and respondent self-reported alcohol consumption. Acetaminophen safety information was provided to all persons regardless of participation in the study. Of the 102 patients who chose to participate, 79% recognized acetaminophen as a synonym of Tylenol, whereas only 9% identified APAP as a frequently used abbreviation. One third of respondents thought acetaminophen was synonymous with ibuprofen and naproxen. Approximately one fourth of patients correctly identified the then maximum recommended daily acetaminophen dose of 4 g. Seventy-eight percent of patients correctly identified hepatotoxicity as the most common serious adverse effect. We conclude that patient deficiencies in knowledge of acetaminophen recognition, dosing, and toxicity warrant public education by health professionals at all levels of interaction. Current initiatives are promising; however, further efforts are required.
由于存在故意以及更令人担忧的非故意过量服用相关肝毒性风险,对乙酰氨基酚的使用目前正受到美国食品药品监督管理局(FDA)越来越严格的审查。对乙酰氨基酚估计占所有急性肝衰竭诊断病例的48%。本研究的目的是评估患者对含对乙酰氨基酚产品安全使用及潜在毒性的认知和了解情况。作者采用来自一家大型家庭医学诊所候诊室的便利样本进行了一项为期两周的描述性研究。调查问题评估了识别对乙酰氨基酚的能力、对当前推荐最大日剂量的了解、受访者对乙酰氨基酚的使用模式、与对乙酰氨基酚相关的常见不良反应以及受访者自我报告的饮酒情况。无论是否参与研究,均向所有人提供了对乙酰氨基酚安全信息。在选择参与的102名患者中,79%将对乙酰氨基酚识别为泰诺的同义词,而只有9%将APAP识别为常用缩写。三分之一的受访者认为对乙酰氨基酚与布洛芬和萘普生同义。约四分之一的患者正确识别出当时推荐的对乙酰氨基酚最大日剂量为4克。78%的患者正确识别出肝毒性是最常见的严重不良反应。我们得出结论,患者在对乙酰氨基酚识别、剂量和毒性知识方面的欠缺需要各级医疗专业人员进行公众教育。当前的举措很有前景;然而,仍需进一步努力。